Combining YTHDF2 siRNA and cisplatin significantly enhanced cisplatin's anti‐tumour effects in chemoresistant ICC PDX models, suggesting new combined therapeutic strategies for ICC.221. Here, YTHDF2 is linked to intrahepatic cholangiocarcinoma.